|Trial||Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction (ExOTIC)
ClinicalTrials.gov Identifier: NCT04303377
|Aim||To investigate the effect of evolocumab in patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI)|
|Study design||Randomized, parallel-group, open-label
All patients will receive standard of care, including high dose of statin ± ezetimibe. Evolocumab 140 mg every 2 weeks will be administered in the acute phase of STEMI.
The duration of the study is 6 months.
|Patients||154 patients with chest pain or equivalent lasting > 20 minutes, with STEMI scheduled for primary PCI. Exclusion criteria included previous MI, percutaneous or surgical myocardial revascularization, ongoing treatment with any statin or ezetimibe, history of congestive heart failure, or cardiogenic shock at presentation.|
|Primary outcome||Reduction in infarct size from baseline to 6 months|